18 years of experience in the generation of complex model systems. Six years head of the EMBL Rome genome engineering services and responsible for design, assembly and QC of DNA-based targeting constructs for mouse mutagenesis. Eight years head of the MRC WIMM genome engineering facility at Oxford University. Responsible for CRISPR based genetic engineering of cell lines, mESCs, zebrafish and alternative model systems. Portfolio of complex HDRT design and assembly, genetic editing (KO, KI, cKO, cKI). Coordination and management of genome engineering activities, the WIMM virus screening facility and a core qRT-PCR genotyping service.
Four years in leading the hiPSC genome engineering activities for the Cell Therapy department of Evotec International in Göttingen. Responsible for all genome engineering activities and associated QCs of stem cell derived ATMPs. Coordination of Evotec CMC efforts for the upcoming tech transfer to a cGMP-compliant process for the generation of an immune shielded master cell bank. Goal: production of allogeneic hiPSC-derived beta cells for treatment of T1D.
18 years of experience in the generation of complex model systems. Six years head of the EMBL Rome genome engineering services and responsible for design, assembly and QC of DNA-based targeting constructs for mouse mutagenesis. Eight years head of the MRC WIMM genome engineering facility at Oxford University. Responsible for CRISPR based genetic engineering of cell lines, mESCs, zebrafish and alternative model systems. Portfolio of complex HDRT design and assembly, genetic editing (KO, KI, cKO, cKI). Coordination and management of genome engineering activities, the WIMM virus screening facility and a core qRT-PCR genotyping service.
Four years in leading the hiPSC genome engineering activities for the Cell Therapy department of Evotec International in Göttingen. Responsible for all genome engineering activities and associated QCs of stem cell derived ATMPs. Coordination of Evotec CMC efforts for the upcoming tech transfer to a cGMP-compliant process for the generation of an immune shielded master cell bank. Goal: production of allogeneic hiPSC-derived beta cells for treatment of T1D.